Search results
Results from the WOW.Com Content Network
Antiplatelet drugs effect may be affected by patient's medications, current medical conditions, food and supplements taken. Antiplatelet drugs effect may be increased or decreased. An increase in antiplatelet effect would increase the risk of bleeding and could cause prolonged or excessive bleeding.
Rare (<0.1%) [ edit ] Neuroleptic malignant syndrome (Combination of fever , muscle stiffness, faster breathing , sweating , reduced consciousness, and sudden change in blood pressure and heart rate )
Therefore there is no definite evidence on the drug interaction effect on mortality. [38] For patients with high risk of gastrointestinal bleeding, the risk outweighs the possible adverse cardiovascular effects. It should therefore be recommended to those patients to combine clopidogrel with less CYP2C19 inhibiting PPI's, such as pantoprazole. [38]
The most serious side effects associated with ticlopidine are those that affect the blood cells, although these life-threatening complications are relatively rare. The most common side effects include: [1] Diarrhea; Nausea; Dyspepsia; Rash; Abdominal pain; Ticlopidine may also cause an increase in cholesterol, triglycerides, liver enzymes, and ...
Available antiplatelet drugs have delayed onset and offset of action. [10] Since cangrelor's effects are immediate and quickly reversed, it is a more desirable drug for elective treatment of stenotic coronary arteries, high risk acute coronary syndromes treated with immediate coronary stenting, and for bridging those surgery patients who ...
Eptifibatide is used to reduce the risk of acute cardiac ischemic events (death and/or myocardial infarction) in patients with unstable angina or non-ST-segment-elevation (e.g., non-Q-wave) myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes) both in patients who are to receive non surgery (conservative) medical treatment and those undergoing percutaneous coronary ...
Tirofiban, sold under the brand name Aggrastat, is an antiplatelet medication.It belongs to a class of antiplatelets named glycoprotein IIb/IIIa inhibitors.Tirofiban is a small molecule inhibitor of the protein-protein interaction between fibrinogen and the platelet integrin receptor GP IIb/IIIa and is the first drug candidate whose origins can be traced to a pharmacophore-based virtual ...
In the US, ticagrelor is indicated to reduce the risk of stroke in people with acute ischemic stroke or high-risk transient ischemic attack. [5]In the EU, ticagrelor, co-administered with acetylsalicylic acid (aspirin), is indicated for the prevention of atherothrombotic events in adults with acute coronary syndromes or a history of myocardial infarction and a high risk of developing an ...